Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy (kdSdc1 and mutant)
Ontology highlight
ABSTRACT: Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy (kdSdc1 and mutant)
PROVIDER: PRJNA1071144 | ENA |
REPOSITORIES: ENA
ACCESS DATA